Greetings, and welcome to the DURECT Corporation Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star and then zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Tim Papp. Thank you. You may begin. Good afternoon, and welcome to DURECT Corporation's Third Quarter 2024 Earnings Conference Call. This is Tim Papp, Chief Financial Officer of DURECT. Before we begin, I would like to remind you of our Safe Harbor Statement. During the course of this call, we may make forward-looking statements regarding DURECT's products and development, expected product benefits, our development plans, future clinical trials, or projected financial results. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Further information regarding these and other risks can be found in our SEC filings, including our 10-K and 10-Qs under the heading Risk Factors. To begin, I would like to review our Third Quarter 2024 financial results. Total revenues in the third quarter were $1.9 million compared to $1.7 million in 2023. 2024 revenues were higher primarily due to an increase in product sales, partially offset by a decrease in revenue from collaborations. R&D expense was $2.2 million in the third quarter of 2024 compared to $7.2 million for the prior year. The decrease was primarily due to lower clinical trial-related expenses and lower employee-related costs. SG&A expenses were $3.2 million in the third quarter of 2024 compared to $3.8 million for the prior year. The decrease was primarily due to lower employee, professional services, and legal expenses. As of September 30, 2024, we had cash and investments of $10.5 million, and our cash utilization in the third quarter was $5.3 million. We believe our cash on hand is sufficient to fund operations through the first quarter of 2025. Lastly, Innocoll has notified us that they are terminating the licensing agreement related to POSIMIR. We are in the process of evaluating our options for POSIMIR, but given that we have not been receiving royalties in recent quarters, we do not expect that this will have a material financial impact for DURECT. Now, I would like to turn the call over to Jim for a business update. Thank you, Tim. Hello, everyone, and thank you for joining us today. DURECT's priority continues to be initiation of the confirmatory phase III clinical trial of larsucosterol in alcohol-associated hepatitis, or AH, and I'm excited to share an update on our progress. As we finalize preparations for the trial, we continue to have positive dialogue with the FDA, utilizing the advantages offered under our Breakthrough Therapy designation. During the quarter, we held a Type B meeting with the FDA and reached an agreement on key aspects of our planned phase III trial design. The phase III trial is designed as a randomized, double-blind, placebo-controlled, multicenter study that will be conducted in patients with severe AH in the U.S. We plan to enroll approximately 200 patients who will be randomized one-to-one to either 30 milligrams of larsucosterol or placebo. The primary outcome measure will be a 90-day survival endpoint. We are conducting this trial at U.S. sites to avoid the variability we observed in healthcare provision at ex-U.S. sites in the prior AFIRM study. For example, we observed a difference across regions of the world in the time to treat patients in the AFIRM trial. These data will be presented in an oral presentation at the AASLD meeting this weekend. The dosing regimen in phase III is consistent with AFIRM, with patients receiving the first dose on day one and, if still hospitalized, a second dose on day four. This trial design leverages the data from our phase II-B AFIRM trial and the feedback we received from the FDA through our Type B meeting held under the Breakthrough designation. As a reminder, in AFIRM, both doses of larsucosterol reduced mortality by nearly 60% in the U.S. patients, who represented 76% of the total number of patients in the trial. The FDA has confirmed that a single pivotal trial would be sufficient to support an NDA filing, and with Breakthrough Therapy, we have the opportunity to submit the NDA on a rolling basis. We are preparing to initiate the trial as soon as we can, subject to obtaining sufficient capital, and our goal is to have top-line data within two years of initiation. We remain committed to obtaining approval for larsucosterol as expeditiously as possible and ultimately bringing this potentially lifesaving therapeutic to patients with no effective treatment options today. We have already undertaken important steps to prepare for initiating the trial, including starting the process of onboarding clinical sites and selecting a CRO to help manage the trial. We expect to report top-line data within two years of initiating the trial. We continue to analyze the AFIRM data and will have additional data presented at the AASLD meeting during the next week. We have an oral presentation of the time-to-treatment data that I mentioned previously. We also have two poster presentations, one on liver transplants and the other on drinking behavior of patients who participated in the AFIRM trial. We remain encouraged by the strong interest from hepatology thought leaders and key opinion leaders for the AFIRM results and their continued support for larsucosterol's potential to provide a clinically meaningful survival benefit in patients. As a brief reminder, our phase II-B AFIRM trial was a placebo-controlled, double-blind, multinational study with two active arms of 30 milligrams and 90 milligrams of larsucosterol and a placebo arm of approximately 100 patients each. In total, we randomized 307 patients with severe AH from a global network of clinical sites. Our sites included renowned liver centers in the United States, Australia, the E.U., and the U.K., and we had the honor of working with some of the world's preeminent thought leaders AH. The top-line results in the key secondary endpoint of mortality at 90 days showed a 41% reduction with a 30 mg dose of larsucosterol and a 35% reduction with a 90 mg dose of larsucosterol as compared with placebo. Even more impressive results were observed in the U.S. population, which comprised three-quarters of the total enrollment in AFIRM. That was 232 out of 307 patients. In the U.S., we saw reductions in 90-day mortality of 57% and 58% for the 30ml and 90 mg arms, respectively, compared with placebo. Although not part of the original trial statistical analysis plan, the p-values for these results were both approximately 0.01. Very importantly, larsucosterol exhibited an excellent safety profile, with no serious adverse events in either arm and greater than 20% reductions in the total number of treatment-emergent adverse events for both active arms when compared with the placebo group in the severely ill patients. Ultimately, these clinically meaningful reductions in mortality, coupled with the reduction in adverse events in the severely ill patients, reinforce the compelling risk-reward proposition of larsucosterol. We continue to believe that the AFIRM data provide compelling evidence that larsucosterol could represent a safe and effective therapy with lifesaving potential for patients. There are no approved therapies for today, so if larsucosterol meets our expectation in the phase III and we gain approval, it would likely be the first FDA-approved treatment for this disease and establish a new standard of care. AH is the cause of more than 160,000 hospitalizations each year in the U.S., and with a 90-day mortality rate of approximately 30%, is responsible for tens of thousands of deaths each year. In addition to its high mortality rate, AH represents a significant cost to the U.S. healthcare system. Hospitalizations attributed to incur charges between $67,000-$180,000 per patient, a total charge to hospitals of approximately $10 billion annually. As a result, larsucosterol could potentially save thousands of lives each year while representing a potential blockbuster opportunity in the U.S. alone that could simultaneously provide overall cost savings to the healthcare system. We would now like to take any questions you may have. Thank you. We will now be conducting question-and-answer session. If you would like to ask a question, please press star and then one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star and then two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your headset before pressing the star keys. The first question we have is from François Brisebois of Oppenheimer. Please go ahead. Hi, this is Dan on for Frank. Thanks for taking our questions. At this time, are you sharing anything about your strategy for the onboarding of sites? Would you be targeting the same sites in the U.S. as in the AFIRM trial? Were there any sites that were faster enrolling? Sites, any color there? Yeah, we definitely are going to be using a number of the same sites, and we've been spending this time actually putting in place confidentiality agreements and putting in place the agreements because when starting any clinical trial, it's the paperwork, the legal component of it all that takes the longest from starting it. But WeiQi is on the line. I'll let her also speak to that. WeiQi, any thoughts on the specific approach you're taking with these U.S. sites? Yes. We actually will include at least 60%-70% of the AFIRM trial sites in the U.S. for our phase III trial. Thanks for that. And with respect to you highlighted that there were some time-to-treatment differences around the world. I'm wondering if there were any geographical differences within the U.S., or was this mostly a U.S. versus ex-U.S. phenomena? Once again, I'll let WeiQi speak to that first. Go ahead, WeiQi. Yeah, there were huge differences of time-to-treat, of the regional differences for the time-to-treat, which we are going to present at the AASLD meeting on the 18th of November. Within U.S., of course, there might be site-to-site variations, which we did observe that. But however, because the end numbers from U.S. region is much bigger, so it more or less overcomes that variation because of smaller sample size from ex-U.S. regions, so that further exaggerating that time-to-treat variations. That's why this phase III trial will be focusing on U.S., at least for now, for the phase III. That makes sense. Thanks for taking my questions. Sure. The next question we have is from Ed Arce of H.C. Wainwright. Please go ahead. Hello, everyone. Good afternoon. This is Thomas. I'm asking a couple of questions for Ed. Thank you for taking our questions. So first, besides funding, what are some other preparations that are needed for larsucosterol to enter phase III? The funding, obviously, is the most important piece, and once that's in place, we feel like we can complete the trial from about two years from when we established and start the trial. The things we're doing now are things that do have a long lead time and can be done with very little money, and those are putting in place the legal relationships and contracts between ourselves and the various clinical sites as well. We have selected our CRO, which always takes a bit of time, so that's been done. We're just doing everything we can in preparation to start the trial as quickly as possible once we have the funding in place. I see. So it sounds like pretty much everything's ready to go, but just waiting for the funding. Exactly. I suppose to the issue of funding, can you give a ballpark figure of how much the phase III study is estimated to cost, especially given the relatively short initiation to read-out timeline that you pointed out in about two years? Yeah. I don't know. Tim, do you want to maybe speak to that? Sure. Yeah, so as Jim mentioned, we've been working with CROs, and we've had a competitive bid process to get their estimates for what the phase III trial would cost from an external cost perspective, and that's in the $20 million-$25 million range. And then, obviously, on top of that comes the G&A associated with running the business here at DURECT. So we think our burn's probably in the $3 million-$4 million a quarter range once we are scaled to start the trial. Got it. Thank you again for taking our questions and looking forward to additional progress. Thank you, Thomas. Good talking to you. The next question we have is from Carl Byrnes of Northland Capital Markets. Please go ahead. Thanks for the question. Actually, most of my questions related to the trial that I answered. So kind of moving over just a bit, were there any royalty revenue recognized from Innocoll in the third quarter? And if so, can you quantify that? Thanks. Sure. I'll let Tim speak to it. Yeah, there were none. Okay, great. Thank you. Sure. At this time, we have no further questions, and I would like to hand the floor back over to Jim Brown for any closing remarks. I want to thank you for your time today. We all do. As always, if you have any further questions, please reach out to us. We look forward to catching up. Thank you so much and take care. Ladies and gentlemen, that concludes today's conference. Thank you for joining us. You may now disconnect your lines.